LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non‐small cell lung cancer

• Published in: Clinical and translational medicine Vol. 12; no. 4; pp. e792 - n/a
• Main Authors: Gao, Yanping, Zhang, Nannan, Zeng, Zihang, Wu, Qiuji, Jiang, Xueping, Li, Shuying, Sun, Wenjie, Zhang, Jianguo, Li, Yangyi, Li, Jiali, He, Fajian, Huang, Zhengrong, Zhang, Jinfang, Gong, Yan, Xie, Conghua
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.04.2022; John Wiley and Sons Inc; Wiley
• Subjects: Antibodies; Cancer therapies; Carcinogenesis - genetics; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - metabolism; Carcinoma, Non-Small-Cell Lung - pathology; Cell growth; cGAS/STING; Clinical medicine; Cloning; Cytotoxicity; DNA damage; Genes; Humans; Immunotherapy; Lung cancer; Lung Neoplasms - genetics; Lung Neoplasms - metabolism; Lung Neoplasms - pathology; Male; Medical prognosis; NSCLC; Nucleotidyltransferases - genetics; Nucleotidyltransferases - metabolism; PCAT1; Plasmids; Polymerase chain reaction; Prostate cancer; Radiation therapy; radioimmune responses; RNA, Long Noncoding - genetics; RNA, Long Noncoding - metabolism; SOX2; SOXB1 Transcription Factors - genetics; United States > US; China; SOX2; NSCLC; radioimmune responses; PCAT1; cGAS/STING

Background The expression of long non‐coding RNA (lncRNA) prostate cancer‐associated ncRNA transcripts 1 (PCAT1) is increased in non‐small cell lung cancer (NSCLC). It stimulates tumour growth and metastasis, but its role in the radioimmune responses remain unknown. We aimed to explore the impacts o...